90Y-PET/CT Imaging Quantification for Dosimetry in Peptide Receptor Radionuclide Therapy: Analysis and Corrections of the Impairing Factors

2015 ◽  
Vol 30 (5) ◽  
pp. 200-210 ◽  
Author(s):  
Cinzia Fabbri ◽  
Mirco Bartolomei ◽  
Vincenzo Mattone ◽  
Michela Casi ◽  
Francesco De Lauro ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Ct Imaging ◽  
Peptide Receptor ◽  
Pet Ct ◽  
90Y Pet

90Y-PET/CT imaging quantification in peptide receptor radionuclide therapy (PRRT)

2016 ◽  
Vol 32 ◽  
pp. 105 ◽  
Author(s):  
G. Sarti ◽  
V. Mattone ◽  
M. Casi ◽  
F. De Lauro ◽  
S. Sanniti ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Ct Imaging ◽  
Peptide Receptor ◽  
Pet Ct ◽  
90Y Pet

scholarly journals Can the Standardized Uptake Values derived from Diagnostic 68Ga-DOTATATE PET/CT Imaging Predict the Radiation Dose delivered to the Metastatic Liver NET Lesions on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy?

2013 ◽  
Vol 47 (1) ◽  
pp. 7-13 ◽  
Author(s):  
Baljinder Singh ◽  
Vikas Prasad ◽  
Christiane Schuchardt ◽  
Harshad Kulkarni ◽  
Richard P Baum
Keyword(s):  
Radiation Dose ◽  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Ct Imaging ◽  
Neuroendocrine Neoplasms ◽  
Liver Lesions ◽  
Peptide Receptor ◽  
Standardized Uptake Values ◽  
Pet Ct ◽  
Metastatic Liver

ABSTRACT Introduction Neuroendocrine neoplasms express somatostatin receptors, enabling the use of somatostatin analogs for molecular imaging, when labeled with the positron-emitter 68Ga for receptor positron emission tomography/computed tomography (PET/CT), and targeted radionuclide therapy, when labeled with beta-emitters, e.g. 90Y and 177Lu. Aim To investigate if 68Ga-DOTATATE PET-derived standardized uptake values (SUV) correlate with the dose delivered to the liver lesions following 177Lu-DOTATATE radionuclide therapy in patients with neuroendocrine neoplasms. Materials and methods Twelve adult (8M: 4F; mean age: 55.9 ± 14.5 years; range: 23-78 years) patients with documented neuroendocrine tumor (NET) disease and liver metastases were enrolled in the study. Ten patients were subjected to 68Ga-DOTATATE and one patient each underwent 68Ga-DOTATOC and 68Ga-DOTANOC diagnostic PET/CT imaging. Subsequently, on the basis of positive PET/CT scan findings for the metastatic NET disease, all these patients were subjected to peptide receptor radionuclide therapy (PRRNT) with 177Lu-DOTATATE. The reconstructed PET/CT data was used to calculate the SUVs on the identifiable liver lesions. The scintigraphic data acquired (anterior and posterior whole body images) following therapeutic doses of 177Lu-DOTATATE were subjected to the quantitative analysis (HERMES workstation and OLINDA/EXM software) to calculate the dose delivered to the hepatic lesions. Results The initial results of this preliminary study indicate poor correlation between SUV and the tumor dose and the linear regression analysis provided R2 values which explained only a small fraction of the total variance. Conclusion The SUVs derived from 68Ga-DOTA-peptide PET/CT images should be used with caution for the prediction of tumor dose on 177Lu-DOTA-peptide therapy as there are large intra- and interpatient variability. Further studies with large numbers of patients are warranted to establish such a correlation between SUV, tumor dose and the response assessment. How to cite this article Singh B, Prasad V, Schuchardt C, Kulkarni H, Baum RP. Can the Standardized Uptake Values derived from Diagnostic 68Ga-DOTATATE PET/CT Imaging Predict the Radiation Dose delivered to the Metastatic Liver NET Lesions on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy? J Postgrad Med Edu Res 2013;47(1):7-13.

scholarly journals Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Sowon Oh ◽  
Vikas Prasad ◽  
Dong Soo Lee ◽  
R. P. Baum
Keyword(s):  
Glucose Metabolism ◽  
Neuroendocrine Tumors ◽  
Fdg Pet ◽  
Radionuclide Therapy ◽  
Somatostatin Receptor ◽  
Peptide Receptor Radionuclide Therapy ◽  
Receptor Expression ◽  
Peptide Receptor ◽  
Pet Ct ◽  
Fdg Pet Ct

The heterogeneous nature of the neuroendocrine tumors (NET) makes it challenging to find one uniformly applicable management protocol which is especially true for diagnosis. The discovery of the overexpression of somatostatin receptors (SMS-R) on neuroendocrine tumor cells lead to the generalized and rapid acceptance of radiolabeled somatostatin receptor analogs for staging and restaging of NET as well as for Peptide Receptor Radionuclide Therapy (PRRNT) using Y-90 and Lu-177 DOTATATE/DOTATOC. In this present work we tried to look in to the effect of PRRNT on the glucose metabolism assessed by F-18 FDG PET/CT and SMS-R density assessed by Ga-68 DOTANOC PET/CT. We observed a complex relationship between the somatostatin receptor expression and glucose metabolism with only 56% (77/138) of the lesions showing match, while the others show mismatch between the receptor status and metabolism. The match between receptor expression and glucose metabolism increases with the grade of NET. In grade 3 NET, there is a concurrence between the changes in glucose metabolism and somatostatin receptor expression. PRRNT was found to be more effective in lesions with higher receptor expression.

68Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours

2019 ◽  
Vol 141 ◽  
pp. 108-115 ◽  
Author(s):  
Rohini Sharma ◽  
Wai Meng Wang ◽  
Siraj Yusuf ◽  
Joanne Evans ◽  
Ramya Ramaswami ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Neuroendocrine Tumours ◽  
Peptide Receptor Radionuclide Therapy ◽  
Peptide Receptor ◽  
Pet Ct

Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor (NET) patients (SCAN): Awareness of specialized techniques and latest interventions.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e16708-e16708
Author(s):  
Mark McDonnell ◽  
Dirk Van Genechten ◽  
Teodora Kolarova ◽  
Dermot O'Toole ◽  
Harjit Singh ◽  
...  
Keyword(s):  
Treatment Option ◽  
Radionuclide Therapy ◽  
Online Survey ◽  
Peptide Receptor Radionuclide Therapy ◽  
Standard Of Care ◽  
Peptide Receptor ◽  
Monitoring Tools ◽  
Pet Ct ◽  
Small Intestinal ◽  
Ongoing Monitoring

e16708 Background: SCAN measured global readiness to provide diagnostics and treatments for NET patients in terms of awareness, availability, quality and affordability. This analysis focused on patient and healthcare professional (HCP) awareness of NET diagnostics and treatments. Methods: During Sept-Nov 2019, NET patients and HCPs completed an online survey (available in 14 languages). Results: There were 2795 respondents from 68 countries across 6 continents (2359 patients/carers; 436 HCPs). Primary NETs were most often gastroenteropancreatic NETs (GEP NET; 71% [1408/1983]), particularly small intestinal (35% [690/1983]) or pancreatic (20% [402/1983]). Biopsy was the most well-known diagnostic option in the overall NET patient group (82% [1917/2325]), the GEP NET patient subgroup (83% [1156/1395]) and HCPs (94% [411/435]), followed by CT (all patients: 81% [1874/2325]; GEP NET: 80% [1118/1395]; HCPs: 86% [376/435]). More HCPs were aware of specialized diagnostics, such as 68Ga-DOTA PET CT (HCP 81% [353/435]) and chromogranin A (CgA; 79% [344/435]), than patients (all: 68% [1574/2325] & 62% [1451/2325], respectively; GEP NET: 69% [962/1395] & 67% [936/1395]). The vast majority of all patients (87% [1983/2275]), GEP NET patients (89% [1215/1363]) and HCPs (91% [392/431]) knew surgery was a treatment option. Somastatin analogues were recognised as a treatment option by 90% of HCPs (387/431), but only 75% of GEP NET patients (1019/1363) and 70% of all NET patients (1599/2275). Nearly a quarter of HCPs (22% [95/431]) and one-third of patients (all: 33% [755/2275]; GEP NET: 30% [409/1363]) had not heard of peptide receptor radionuclide therapy (PRRT). The majority of patients (all: 88% [2007/2273]; GEP NET: 89% [1213/1370]) and HCPs (93% [396/425]) were aware of conventional imaging, such as CT/MRI/ultrasound, being used for ongoing monitoring of NETs. Approximately a third of all NET patients and a quarter of HCPs were unware CgA (patients: 32% [723/2273]; HCPs: 22% [94/425]) or 68Ga-DOTA PET CT (patients: 29% [670/2273]; HCPs: 24% [102/425]) were ongoing monitoring tools. Similarly, CgA and 68Ga-DOTA PET CT were not recognized by 27% of GEP NET patients (364/1370 & 371/1370, respectively). Conclusions: Increased awareness of NET diagnostics and treatments, particularly newer, more specialized tools, amongst both HCPs and patients is required to ensure continued advancements and improvements in the global standard of care for NETs.

Sign in / Sign up

Export Citation Format

Share Document